Entries by Thomas Gabrielczyk

Allergies: Public Enemy Number One

The concept has been around for more than a century, but recent advances in the field are causing numerous experts to say it’s widely under­used. The goal of allergen immunotherapy (AIT) is to induce a specific immune tolerance by confronting patients with increasing levels of allergens. AIT developers are now working on improving efficacy and safety, while at the same time trying to speed up the still lengthy process of desensitisation. Peanuts in particular are in the crosshairs, as they cause one of the most life-threatening common allergies in humans.

Diabetes: J&J and Seventure Partners launch investment

European venture capitalist Seventure Partners and  Johnson & Johnson have invested US$12m in Israel-based DayTwo. Based on HbA1c, lifestyle factors and genetic analysis of the individual microbiome, the company’s app analyses the individual microbiome to predict blood sugar responses to thousands of different foods.

CHMP recommends several biologics

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended two antivirals, one biosimilar and two cancer meds for approval at its June meeting.

Update of bioeconomy strategy unsure

Uncertainty regarding the amount of future funding and political support from the European Commission for the bioeconomy is set to hamper investments into the switch from oil-based industry production to renewable, bio-based manufacture in Europe. The schedule for the review of the bioeconomy strategy has been delayed until the end of 2017. More importantly, it is not yet certain if the strategy will be updated.

Roche’s lampalizumab halts geographic atrophy

A publication in Science Translational Medicine shows that Roche has a rising star in the 15 million patient market of age-related macular degeneration (AMD). In a Phase II trial, US and German researchers showed efficacy in geographic atrophy, an advanced stage of AMD, which has currently no treatment.

Epigenetic drugs set to boost immunoncology

German oncologists have unveiled that market-approved inhibitors of DNA methyltransferases (DMNTi) and histone deacetylases (HDACi) act through expression of cancer neoantigens. They already have a biomarker test to identify responders.